Comparative Pharmacology
Head-to-head clinical analysis: CORTONE versus ENTOCORT EC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTONE versus ENTOCORT EC.
CORTONE vs ENTOCORT EC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, leading to decreased inflammation through inhibition of phospholipase A2, reduced cytokine production, and suppression of immune cell migration.
Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory effects via inhibition of inflammatory mediators such as cytokines and prostaglandins.
Oral: 25-300 mg daily in 1-4 divided doses; typical initial dose 150-300 mg daily. IM/IV: 100-500 mg every 6-12 hours.
9 mg orally once daily in the morning for up to 8 weeks.
None Documented
None Documented
Terminal half-life: 8-12 hours (cortisone) but cortisone is a prodrug; active metabolite cortisol has half-life 1.5-2 hours. Clinical context: duration of action 8-12 hours due to prolonged receptor occupancy.
Terminal elimination half-life is approximately 2-3 hours; clinically, the extended intestinal release formulation maintains local activity despite short systemic half-life.
Renal: ~90% as metabolites (glucuronides and sulfates), ~5% unchanged; biliary/fecal: ~5%.
Primarily fecal (60-70%) with minimal renal excretion (<10%); extensively metabolized hepatically, metabolites excreted in bile and feces.
Category C
Category C
Corticosteroid
Corticosteroid